List of Contents

Strep Throat Treatment Market Size, Share, and Trends 2024 to 2033

Strep Throat Treatment Market (By Disease Type: Acute Strep Throat, Pharyngitis, Tonsillitis, Laryngitis, By Treatment Type: Antibiotics, Pain Relievers; By Diagnosis: Antibody Test, Physical Examination, Throat Culture; By Route Of Administration: Oral, Topical, Injectable; By End-use: Hospitals, Specialty Clinics, Diagnostic Laboratories; By Distribution Channel) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033

  • Last Updated : June 2024
  • Report Code : 4422
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Strep Throat Treatment Market 

5.1. COVID-19 Landscape: Strep Throat Treatment Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Strep Throat Treatment Market, By Disease Type

8.1. Strep Throat Treatment Market, by Disease Type, 2024-2033

8.1.1. Acute Strep Throat

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Pharyngitis

8.1.2.1. Market Revenue and Forecast (2021-2033)

8.1.3. Tonsillitis

8.1.3.1. Market Revenue and Forecast (2021-2033)

8.1.4. Laryngitis

8.1.4.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global Strep Throat Treatment Market, By Treatment Type

9.1. Strep Throat Treatment Market, by Treatment Type, 2024-2033

9.1.1. Antibiotics

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Pain Relievers

9.1.2.1. Market Revenue and Forecast (2021-2033)

Chapter 10. Global Strep Throat Treatment Market, By Diagnosis

10.1. Strep Throat Treatment Market, by Diagnosis, 2024-2033

10.1.1. Antibody Test

10.1.1.1. Market Revenue and Forecast (2021-2033)

10.1.2. Physical Examination

10.1.2.1. Market Revenue and Forecast (2021-2033)

10.1.3. Throat Culture

10.1.3.1. Market Revenue and Forecast (2021-2033)

Chapter 11. Global Strep Throat Treatment Market, By Route Of Administration

11.1. Strep Throat Treatment Market, by Route Of Administration, 2024-2033

11.1.1. Oral

11.1.1.1. Market Revenue and Forecast (2021-2033)

11.1.2. Topical

11.1.2.1. Market Revenue and Forecast (2021-2033)

11.1.3. Injectable

11.1.3.1. Market Revenue and Forecast (2021-2033)

Chapter 12. Global Strep Throat Treatment Market, By End-use

12.1. Strep Throat Treatment Market, by End-use, 2024-2033

12.1.1. Hospitals

12.1.1.1. Market Revenue and Forecast (2021-2033)

12.1.2. Specialty Clinics

12.1.2.1. Market Revenue and Forecast (2021-2033)

12.1.3. Diagnostic Laboratories

12.1.3.1. Market Revenue and Forecast (2021-2033)

Chapter 13. Global Strep Throat Treatment Market, By Distribution Channel

13.1. Strep Throat Treatment Market, by Distribution Channel, 2024-2033

13.1.1. Hospital Pharmacy

13.1.1.1. Market Revenue and Forecast (2021-2033)

13.1.2. Retail Pharmacy

13.1.2.1. Market Revenue and Forecast (2021-2033)

13.1.3. Online Pharmacy

13.1.3.1. Market Revenue and Forecast (2021-2033)

Chapter 14. Global Strep Throat Treatment Market, Regional Estimates and Trend Forecast

14.1. North America

14.1.1. Market Revenue and Forecast, by Disease Type (2021-2033)

14.1.2. Market Revenue and Forecast, by Treatment Type (2021-2033)

14.1.3. Market Revenue and Forecast, by Diagnosis (2021-2033)

14.1.4. Market Revenue and Forecast, by Route Of Administration (2021-2033)

14.1.5. Market Revenue and Forecast, by End-use (2021-2033)

14.1.6. Market Revenue and Forecast, by Distribution Channel (2021-2033)

14.1.7. U.S.

14.1.7.1. Market Revenue and Forecast, by Disease Type (2021-2033)

14.1.7.2. Market Revenue and Forecast, by Treatment Type (2021-2033)

14.1.7.3. Market Revenue and Forecast, by Diagnosis (2021-2033)

14.1.7.4. Market Revenue and Forecast, by Route Of Administration (2021-2033)

14.1.8. Market Revenue and Forecast, by End-use (2021-2033)

14.1.8.1. Market Revenue and Forecast, by Distribution Channel (2021-2033) 

14.1.9. Rest of North America

14.1.9.1. Market Revenue and Forecast, by Disease Type (2021-2033)

14.1.9.2. Market Revenue and Forecast, by Treatment Type (2021-2033)

14.1.9.3. Market Revenue and Forecast, by Diagnosis (2021-2033)

14.1.9.4. Market Revenue and Forecast, by Route Of Administration (2021-2033)

14.1.10. Market Revenue and Forecast, by End-use (2021-2033)

14.1.11. Market Revenue and Forecast, by Distribution Channel (2021-2033)

14.1.11.1.

14.2. Europe

14.2.1. Market Revenue and Forecast, by Disease Type (2021-2033)

14.2.2. Market Revenue and Forecast, by Treatment Type (2021-2033)

14.2.3. Market Revenue and Forecast, by Diagnosis (2021-2033)

14.2.4. Market Revenue and Forecast, by Route Of Administration (2021-2033) 

14.2.5. Market Revenue and Forecast, by End-use (2021-2033)

14.2.6. Market Revenue and Forecast, by Distribution Channel (2021-2033)

14.2.7.

14.2.8. UK

14.2.8.1. Market Revenue and Forecast, by Disease Type (2021-2033)

14.2.8.2. Market Revenue and Forecast, by Treatment Type (2021-2033)

14.2.8.3. Market Revenue and Forecast, by Diagnosis (2021-2033)

14.2.9. Market Revenue and Forecast, by Route Of Administration (2021-2033) 

14.2.10. Market Revenue and Forecast, by End-use (2021-2033)

14.2.10.1. Market Revenue and Forecast, by Distribution Channel (2021-2033) 

14.2.11. Germany

14.2.11.1. Market Revenue and Forecast, by Disease Type (2021-2033)

14.2.11.2. Market Revenue and Forecast, by Treatment Type (2021-2033)

14.2.11.3. Market Revenue and Forecast, by Diagnosis (2021-2033)

14.2.12. Market Revenue and Forecast, by Route Of Administration (2021-2033)

14.2.13. Market Revenue and Forecast, by End-use (2021-2033)

14.2.14. Market Revenue and Forecast, by Distribution Channel (2021-2033)

14.2.14.1.

14.2.15. France

14.2.15.1. Market Revenue and Forecast, by Disease Type (2021-2033)

14.2.15.2. Market Revenue and Forecast, by Treatment Type (2021-2033)

14.2.15.3. Market Revenue and Forecast, by Diagnosis (2021-2033)

14.2.15.4. Market Revenue and Forecast, by Route Of Administration (2021-2033)

14.2.16. Market Revenue and Forecast, by End-use (2021-2033)

14.2.16.1. Market Revenue and Forecast, by Distribution Channel (2021-2033)

14.2.17. Rest of Europe

14.2.17.1. Market Revenue and Forecast, by Disease Type (2021-2033)

14.2.17.2. Market Revenue and Forecast, by Treatment Type (2021-2033)

14.2.17.3. Market Revenue and Forecast, by Diagnosis (2021-2033)

14.2.17.4. Market Revenue and Forecast, by Route Of Administration (2021-2033)

14.2.18. Market Revenue and Forecast, by End-use (2021-2033)

14.2.18.1. Market Revenue and Forecast, by Distribution Channel (2021-2033)

14.3. APAC

14.3.1. Market Revenue and Forecast, by Disease Type (2021-2033)

14.3.2. Market Revenue and Forecast, by Treatment Type (2021-2033)

14.3.3. Market Revenue and Forecast, by Diagnosis (2021-2033)

14.3.4. Market Revenue and Forecast, by Route Of Administration (2021-2033)

14.3.5. Market Revenue and Forecast, by End-use (2021-2033)

14.3.6. Market Revenue and Forecast, by Distribution Channel (2021-2033)

14.3.7. India

14.3.7.1. Market Revenue and Forecast, by Disease Type (2021-2033)

14.3.7.2. Market Revenue and Forecast, by Treatment Type (2021-2033)

14.3.7.3. Market Revenue and Forecast, by Diagnosis (2021-2033)

14.3.7.4. Market Revenue and Forecast, by Route Of Administration (2021-2033)

14.3.8. Market Revenue and Forecast, by End-use (2021-2033)

14.3.9. Market Revenue and Forecast, by Distribution Channel (2021-2033)

14.3.10. China

14.3.10.1. Market Revenue and Forecast, by Disease Type (2021-2033)

14.3.10.2. Market Revenue and Forecast, by Treatment Type (2021-2033)

14.3.10.3. Market Revenue and Forecast, by Diagnosis (2021-2033)

14.3.10.4. Market Revenue and Forecast, by Route Of Administration (2021-2033)

14.3.11. Market Revenue and Forecast, by End-use (2021-2033)

14.3.11.1. Market Revenue and Forecast, by Distribution Channel (2021-2033)

14.3.12. Japan

14.3.12.1. Market Revenue and Forecast, by Disease Type (2021-2033)

14.3.12.2. Market Revenue and Forecast, by Treatment Type (2021-2033)

14.3.12.3. Market Revenue and Forecast, by Diagnosis (2021-2033)

14.3.12.4. Market Revenue and Forecast, by Route Of Administration (2021-2033)

14.3.12.5. Market Revenue and Forecast, by End-use (2021-2033)

14.3.12.6. Market Revenue and Forecast, by Distribution Channel (2021-2033)

14.3.13. Rest of APAC

14.3.13.1. Market Revenue and Forecast, by Disease Type (2021-2033)

14.3.13.2. Market Revenue and Forecast, by Treatment Type (2021-2033)

14.3.13.3. Market Revenue and Forecast, by Diagnosis (2021-2033)

14.3.13.4. Market Revenue and Forecast, by Route Of Administration (2021-2033)

14.3.13.5. Market Revenue and Forecast, by End-use (2021-2033)

14.3.13.6. Market Revenue and Forecast, by Distribution Channel (2021-2033)

14.4. MEA

14.4.1. Market Revenue and Forecast, by Disease Type (2021-2033)

14.4.2. Market Revenue and Forecast, by Treatment Type (2021-2033)

14.4.3. Market Revenue and Forecast, by Diagnosis (2021-2033)

14.4.4. Market Revenue and Forecast, by Route Of Administration (2021-2033)

14.4.5. Market Revenue and Forecast, by End-use (2021-2033)

14.4.6. Market Revenue and Forecast, by Distribution Channel (2021-2033)

14.4.7. GCC

14.4.7.1. Market Revenue and Forecast, by Disease Type (2021-2033)

14.4.7.2. Market Revenue and Forecast, by Treatment Type (2021-2033)

14.4.7.3. Market Revenue and Forecast, by Diagnosis (2021-2033)

14.4.7.4. Market Revenue and Forecast, by Route Of Administration (2021-2033)

14.4.8. Market Revenue and Forecast, by End-use (2021-2033)

14.4.9. Market Revenue and Forecast, by Distribution Channel (2021-2033)

14.4.10. North Africa

14.4.10.1. Market Revenue and Forecast, by Disease Type (2021-2033)

14.4.10.2. Market Revenue and Forecast, by Treatment Type (2021-2033)

14.4.10.3. Market Revenue and Forecast, by Diagnosis (2021-2033)

14.4.10.4. Market Revenue and Forecast, by Route Of Administration (2021-2033)

14.4.11. Market Revenue and Forecast, by End-use (2021-2033)

14.4.12. Market Revenue and Forecast, by Distribution Channel (2021-2033)

14.4.13. South Africa

14.4.13.1. Market Revenue and Forecast, by Disease Type (2021-2033)

14.4.13.2. Market Revenue and Forecast, by Treatment Type (2021-2033)

14.4.13.3. Market Revenue and Forecast, by Diagnosis (2021-2033)

14.4.13.4. Market Revenue and Forecast, by Route Of Administration (2021-2033)

14.4.13.5. Market Revenue and Forecast, by End-use (2021-2033)

14.4.13.6. Market Revenue and Forecast, by Distribution Channel (2021-2033)

14.4.14. Rest of MEA

14.4.14.1. Market Revenue and Forecast, by Disease Type (2021-2033)

14.4.14.2. Market Revenue and Forecast, by Treatment Type (2021-2033)

14.4.14.3. Market Revenue and Forecast, by Diagnosis (2021-2033)

14.4.14.4. Market Revenue and Forecast, by Route Of Administration (2021-2033)

14.4.14.5. Market Revenue and Forecast, by End-use (2021-2033)

14.4.14.6. Market Revenue and Forecast, by Distribution Channel (2021-2033)

14.5. Latin America

14.5.1. Market Revenue and Forecast, by Disease Type (2021-2033)

14.5.2. Market Revenue and Forecast, by Treatment Type (2021-2033)

14.5.3. Market Revenue and Forecast, by Diagnosis (2021-2033)

14.5.4. Market Revenue and Forecast, by Route Of Administration (2021-2033)

14.5.5. Market Revenue and Forecast, by End-use (2021-2033)

14.5.6. Market Revenue and Forecast, by Distribution Channel (2021-2033)

14.5.7. Brazil

14.5.7.1. Market Revenue and Forecast, by Disease Type (2021-2033)

14.5.7.2. Market Revenue and Forecast, by Treatment Type (2021-2033)

14.5.7.3. Market Revenue and Forecast, by Diagnosis (2021-2033)

14.5.7.4. Market Revenue and Forecast, by Route Of Administration (2021-2033)

14.5.8. Market Revenue and Forecast, by End-use (2021-2033)

14.5.8.1. Market Revenue and Forecast, by Distribution Channel (2021-2033)

14.5.9. Rest of LATAM

14.5.9.1. Market Revenue and Forecast, by Disease Type (2021-2033)

14.5.9.2. Market Revenue and Forecast, by Treatment Type (2021-2033)

14.5.9.3. Market Revenue and Forecast, by Diagnosis (2021-2033)

14.5.9.4. Market Revenue and Forecast, by Route Of Administration (2021-2033)

14.5.9.5. Market Revenue and Forecast, by End-use (2021-2033)

14.5.9.6. Market Revenue and Forecast, by Distribution Channel (2021-2033)

Chapter 15. Company Profiles

15.1. Pfizer Inc.

15.1.1. Company Overview

15.1.2. Product Offerings

15.1.3. Financial Performance

15.1.4. Recent Initiatives

15.2. AstraZeneca

15.2.1. Company Overview

15.2.2. Product Offerings

15.2.3. Financial Performance

15.2.4. Recent Initiatives

15.3. Novartis AG

15.3.1. Company Overview

15.3.2. Product Offerings

15.3.3. Financial Performance

15.3.4. Recent Initiatives

15.4. Bayer AG

15.4.1. Company Overview

15.4.2. Product Offerings

15.4.3. Financial Performance

15.4.4. Recent Initiatives

15.5. GSK Plc.

15.5.1. Company Overview

15.5.2. Product Offerings

15.5.3. Financial Performance

15.5.4. Recent Initiatives

15.6. Amgen Inc.

15.6.1. Company Overview

15.6.2. Product Offerings

15.6.3. Financial Performance

15.6.4. Recent Initiatives

15.7. Merck & Co, Inc.

15.7.1. Company Overview

15.7.2. Product Offerings

15.7.3. Financial Performance

15.7.4. Recent Initiatives

15.8. Sanofi

15.8.1. Company Overview

15.8.2. Product Offerings

15.8.3. Financial Performance

15.8.4. Recent Initiatives

15.9. Mitsubishi Chemical Group Corp.

15.9.1. Company Overview

15.9.2. Product Offerings

15.9.3. Financial Performance

15.9.4. Recent Initiatives

15.10. Teva Pharmaceutical Industries Ltd.

15.10.1. Company Overview

15.10.2. Product Offerings

15.10.3. Financial Performance

15.10.4. Recent Initiatives

Chapter 16. Research Methodology

16.1. Primary Research

16.2. Secondary Research

16.3. Assumptions

Chapter 17. Appendix

17.1. About Us

17.2. Glossary of Terms

Proceed To Buy

USD 4900
USD 3800
USD 2100
USD 2100
USD 7500
Immediate Delivery Available

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client

down-arrow-imgGet a Sample

Connect with us now; your solution awaits on the other side!

Contact Us